Latest News Archive

Please select Category, Year, and then Month to display items

Frater Celebration Day Hybrid Conference to be held on 5 May 2022

04 May 2022

Robert Frater — The research efforts in the Department of Cardiothoracic Surgery in the Faculty of Health Sciences, UFS, have come a long way since the establishment of a homograft bank, animal research, and laboratory-based research on cardioplegia by Prof Hannes Meyer in the 1980s

Several world-class scientists and academics in the field of cardiovascular research will converge at the University of the Free State (UFS) on Thursday (5 May 2022) for a one-day hybrid conference to explore and celebrate the massive strides made in this critical field at the UFS Robert W M Frater Cardiovascular Research Centre.

The research efforts in the Department of Cardiothoracic Surgery in the Faculty of Health Sciences, UFS, have come a long way since the establishment of a homograft bank, animal research, and laboratory-based research on cardioplegia by Prof Hannes Meyer in the 1980s. Renewed interest in 2004 under the leadership of Prof Francis E Smit culminated in the establishment of the Robert W M Frater Cardiovascular Research Centre (the Frater Centre) in 2015. This was made possible through donor funding, especially by Dr Robert W M Frater MD PhD (honoris causa, UFS), a South Africa-born New York-based cardiothoracic surgeon, researcher and innovator as infrastructure and project support by the UFS.

The vision of the Frater Centre is to be a leading cardiovascular research institution in South Africa and sub-Saharan Africa. It provides an interdisciplinary training and research platform for scientists and clinicians from different backgrounds to develop as researchers and collaborators in cardiovascular and thoracic surgery and related domains. Activities are focused on the development of African solutions for African problems.

Three main divisions
The Frater Celebration day will highlight the achievements made thus far in a hybrid format in four sessions, which can be attended on a virtual platform or in person. The centre’s local and international collaborators will participate in the programme, and Dr Ronnie van der Merwe, the Group CEO of Mediclinic International, is the guest of honour.

The Frater Centre consists of three main divisions, all of which will form part of the focus of the conference programme in various forms during the day:

1) The Clinical Research Division addresses cardiovascular disease on a broad front, ranging from population and prevalence studies, healthcare solutions and clinical outcomes studies in a specific South African and African context.

2) The Research, Development and Commercialisation division is divided into Tissue Engineering and Cell Biology, Tissue Banking and Large Animal studies, and bioengineering to develop African solutions and technology within these domains.

3) The Simulation Programme provides an integrated interdisciplinary platform for the education and training of individuals and teams in cardiovascular, thoracic, anaesthetic, perfusion technology and related nursing fields in a state-of-the-art simulation unit. The research centre is developing a unique and leading programme and systems in this field. This endeavour is also developing IT models for training, evaluation and research.

The Frater Centre and 4IR
The Centre is firmly established in the fourth industrial revolution. It is new technology-driven, creating new IT platforms and boasts extensive interdisciplinary projects at the biomedical sector's local, national, and international levels.

It is essential to note that the extensive and successful collaboration within the Frater Centre not only exists on institutional level but also nationally and internationally. These collaborators assist, mentor, direct and contribute to the research activities.

Click: Link to the event
Event programme

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept